← All Lifecore Biomedical, INC \de\ filings

Lifecore Biomedical, INC \de\ Schedule 13D activist filings

Filed when an investor crosses five percent and intends to influence the company — the activist disclosure.

NASDAQ
LFCR
Lifecore Biomedical, INC \de\
SCHEDULE: Lifecore Inc. and Stockholders Agree to Merger Support
Lifecore Inc. and Lifecore Biomedical, Inc. stockholders, including Wynnefield Capital entities, have entered into a Voting and Support Agreement to facilitate an upcoming merger.
NASDAQ
LFCR
Lifecore Biomedical, INC \de\
SCHEDULE: Lifecore Biomedical Agrees to Merger Deal
Lifecore Biomedical, Inc. has entered into a merger agreement with Lifecore Inc. and Hazel Merger Sub, Inc., with shareholders to receive $6.28 cash plus a contingent value right per share.
NASDAQ
LFCR
Lifecore Biomedical, INC \de\
SCHEDULE: Legion Partners Boosts Stake in Lifecore Biomedical
Legion Partners, through various entities, has increased its beneficial ownership of Lifecore Biomedical, Inc. to 17.1%, signaling a significant investment and potential strategic interest.
NASDAQ
LFCR
Lifecore Biomedical, INC \de\
SCHEDULE: Lifecore Biomedical: 22NW Fund Seeks Preferred Stock Redemption
22NW Fund has initiated a redemption process for its Series A Preferred Stock in Lifecore Biomedical, signaling a significant shift in its investment.
NASDAQ
LFCR
Lifecore Biomedical, INC \de\
SCHEDULE 13D/A: 22NW Fund Reduces Stake in Lifecore Biomedical to 7.49% Following Significant Share Sales
22NW Fund, LP, a major investor in Lifecore Biomedical, Inc., has reduced its beneficial ownership to 7.49% of the company's common stock after selling over 1.49 million shares in the open market.